| Device | RESOLUTION ctDx FIRST |
| Generic Name | Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System |
| Applicant | Resolution Bioscience, Inc.550 Kirkland Way, Suite 200kirkland, WA 98033 PMA NumberP210040 Date Received12/28/2021 Decision Date12/12/2022 Product Code PQP Advisory Committee Clinical TrialsNCT03785249 Expedited Review Granted? No |
| Date Received | 2021-12-28 |
| Decision Date | 2022-12-12 |
| PMA | P210040 |
| Supplement | S |
| Product Code | PQP |
| Expedited Review | No |
| Combination Product | No |
| Applicant Address | Resolution Bioscience, Inc. 550 Kirkland Way, Suite 200 kirkland, WA 98033 PMA NumberP210040 Date Received12/28/2021 Decision Date12/12/2022 Product Code PQP Advisory Committee Clinical TrialsNCT03785249 Expedited Review Granted? No Combination ProductNo Approval Order Statement The Agilent Resolution CtDx FIRST Assay Is A Qualitative Next Generation Sequencing-based, In Vitro Diagnostic Test That Uses Targeted Hybrid-capture Sequencing Technology To Detect And Report Single Nucleotide Variants (SNVs) And Deletions In Two Genes. The Agilent Resolution CtDx FIRST Assay Utilizes Circulating Cell-free DNA (cfDNA) Isolated From Plasma Of Peripheral Whole Blood Collected In Streck Cell-Free DNA Blood Collection Tubes (BCTs). The Test Is Intended As A Companion Diagnostic To Identify Patients With Non-small Cell Lung Cancer (NSCLC) Who May Benefit From Treatment With The Targeted Therapy Listed In Table 1, In Accordance With The Approved Therapeutic Labeling.Table 1. Companion Diagnostic IndicationIndication: Non-small Cell Lung Cancer (NSCLC); Biomarker: KRAS G12C; Therapy: KRAZATI™ (adagrasib) A Negative Result From A Plasma Specimen Does Not Assure That The Patient’s Tumor Is Negative For Genomic Findings. Patients With NSCLC Who Are Negative For The Biomarker Listed In Table 1 Should Be Reflexed To Tissue Biopsy Testing For Table 1 Biomarker Using An FDA-approved Tumor Tissue Test, If Feasible.Additionally, The Test Is Intended To Provide Tumor Mutation Profiling For SNVs And Deletions In The EGFR Gene For Use By Qualified Health Care Professionals In Accordance With Professional Guidelines In Oncology For Patients With NSCLC. The Test Is For Use With Patients Previously Diagnosed With NSCLC And In Conjunction With Other Laboratory And Clinical Findings.Genomic Findings Other Than Those Listed In Table 1 Are Not Prescriptive Or Conclusive For Labeled Use Of Any Specific Therapeutic Product.The Agilent Resolution CtDx FIRST Assay Is A Single-site Assay Performed At Resolution Bioscience, Inc. Approval OrderApproval Order SummarySummary Of Safety And Effectiveness LabelingLabeling Supplements: |
| Supplement Number | Date | Supplement Type |
|---|---|---|
| P210040 | Original Filing |
| Device ID | PMA | Supp |
|---|---|---|
| 00850059806005 | P210040 | 000 |